New York-listed biopharma company Akari Therapeutics (Nasdaq: AKTX) today announced positive interim data from its Phase III PNH CAPSTONE study in complement inhibitor naïve, transfusion-dependent paroxysmal nocturnal hemoglobinuria (PNH) patients. All patients treated with nomacopan, formerly known as Coversin, achieved the primary endpoint of transfusion independence.
The news saw shares of Akari (which was founded in the UK) leap nearly 22% to $2.11 in early trading, but the stock drifted back to $1.94 (+12.14%) by late morning.
Dr Austin Kulasekararaj of King’s College Hospital, London University, UK, the lead investigator on the long-term CONSERVE safety and efficacy study of nomacopan in patients with PNH, commented: “The study was originally designed to achieve approximately 50% transfusion independence in line with the original eculizumab Phase III PNH pivotal trials, so this initial data is very promising and in combination with the excellent results of the long-term study demonstrate the effectiveness of nomacopan as a complement inhibitor in PNH. In addition, to date nomacopan appears to be well tolerated.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze